Last reviewed · How we verify
Levomilnacipran Hydrochloride Extended-Release Capsules
Levomilnacipran Hydrochloride Extended-Release Capsules is a Serotonin-norepinephrine reuptake inhibitor (SNRI) Small molecule drug developed by Zhejiang Huahai Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Major depressive disorder.
Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by blocking their reuptake at the neuronal synapse.
Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by blocking their reuptake at the neuronal synapse. Used for Major depressive disorder.
At a glance
| Generic name | Levomilnacipran Hydrochloride Extended-Release Capsules |
|---|---|
| Sponsor | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) |
| Target | Serotonin transporter (SERT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the reuptake of both serotonin and norepinephrine, levomilnacipran increases the availability of these neurotransmitters in the synaptic cleft, enhancing their signaling. The extended-release formulation provides sustained drug levels over 24 hours, allowing for once-daily dosing. This mechanism is thought to restore neurotransmitter balance in depression and other mood disorders.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Hyperhidrosis (excessive sweating)
- Constipation
- Tachycardia
- Increased blood pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levomilnacipran Hydrochloride Extended-Release Capsules CI brief — competitive landscape report
- Levomilnacipran Hydrochloride Extended-Release Capsules updates RSS · CI watch RSS
- Zhejiang Huahai Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Levomilnacipran Hydrochloride Extended-Release Capsules
What is Levomilnacipran Hydrochloride Extended-Release Capsules?
How does Levomilnacipran Hydrochloride Extended-Release Capsules work?
What is Levomilnacipran Hydrochloride Extended-Release Capsules used for?
Who makes Levomilnacipran Hydrochloride Extended-Release Capsules?
What drug class is Levomilnacipran Hydrochloride Extended-Release Capsules in?
What development phase is Levomilnacipran Hydrochloride Extended-Release Capsules in?
What are the side effects of Levomilnacipran Hydrochloride Extended-Release Capsules?
What does Levomilnacipran Hydrochloride Extended-Release Capsules target?
Related
- Drug class: All Serotonin-norepinephrine reuptake inhibitor (SNRI) drugs
- Target: All drugs targeting Serotonin transporter (SERT) and norepinephrine transporter (NET)
- Manufacturer: Zhejiang Huahai Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Major depressive disorder
- Compare: Levomilnacipran Hydrochloride Extended-Release Capsules vs similar drugs
- Pricing: Levomilnacipran Hydrochloride Extended-Release Capsules cost, discount & access